A New Meta-Language for Oncology: Invitation to the Global Community — The Rongdu Principles Framework
Zhuanzhi Think Tank（Chengdu Zhuanzhi Lihu Digital Technology Co., Ltd.）
Practice Translation: Yuhang Think Tank（Chengdu Yuhang Patent Agency Firm）
Contact: rongduyuanli@163.com
Services: International Patent Agency | Domestic Patent Agency | Patent化 of Research | Lunar Intellectual Property Registration: www.hrpp.org.cn
A Landmark Achievement
Through the completion of 100 issues of the 'Top Journal Decoding + Disruptive Design' series — covering over 25 cancer types and themes from CA: A Cancer Journal for Clinicians, Nature, Science, and other leading journals — the Rongdu Principles (16 axioms) have been systematically established as a meta-language for oncology.
This is not a claim of discovery. It is a claim of synthesis.
We invite the global oncology community — researchers, clinicians, biotech entrepreneurs, and policymakers — to engage with this framework, to test it, to challenge it, and to apply it.
What Is a 'Meta-Language' in Oncology?
A meta-language is not a set of 'new facts.' It is a framework for organizing facts.
| Traditional oncology provides… | The Rongdu Principles provide… |
|---|---|
| Facts: genes mutate → cancer arises | A coordinate system: where does this phenomenon sit? |
| Facts: TNM stage → prognosis | A mechanism: how does information traverse layers? |
| Facts: chemotherapy → tumor shrinkage | A predictive signal: what does this anomaly indicate? |
| Facts: targeted therapy → resistance | A directional logic: what is the next layer of transition? |
When a clinician encounters a patient with stage IIIA EGFR-mutant NSCLC who develops brain metastases while on osimertinib, the Rongdu Principles meta-language guides three immediate questions:
- Layer localization: Which layer is affected? (P4: EGFR mutation is still present, but P13: the blood-brain barrier has blocked drug penetration)
- Matching analysis: Are the P11 matching conditions met? (Drug-target match is met; drug-BBB-target match is NOT)
- Transition direction: What is the next layer of breakthrough? (BBB penetration enhancement + local radiation, or switching to agents with better CNS penetration)
The Three Core Laws of the Rongdu Principles in Oncology
First Law: The Law of Information Non-Annihilation (P2 + P10)
Cancer information does not disappear; it transfers. The lethality of cancer lies not in 'cell count' but in the 'topological structure of information.' Every 'effective treatment' — surgery (P6), chemotherapy (P4 DNA damage), targeted therapy (P4 signaling blockade) — generates an 'information blast' that is transferred to new layers via the P10 information reuse mechanism.
Key Examples: Pancreatic cancer's 'survival lock' (P4 KRAS self-referential locking → P6 TME high tolerance → P7 zero therapeutic gain); ICI myocarditis 'information amplification' (P10 DAMPs-driven self-referential inflammation lock).
Second Law: The Law of Hierarchical Transition-Matching (P7 + P11)
Every 'evolution' of cancer is a P7 hierarchical transition. Every successful treatment is the establishment of P11 hierarchical matching.
Key Examples: NTRK fusion larotrectinib achieves 75% ORR (highest P11 matching); KRAS G12C inhibitors in NSCLC achieve ~40%-50% ORR (moderate matching); KRAS G12C inhibitors in pancreatic cancer achieve only 20%-25% ORR (P6 TME matching failure).
Third Law: The Law of Boundary Sensing & Active Intervention (P1 + P13 + P14)
Every 'anomalous signal' (P1) in a tumor system is information of the highest priority. And these signals can only be sensed at boundaries (P13). The observer's intervention (P14) determines whether the signal can be decoded into action.
Key Examples: Early-onset colorectal cancer's 'reverse scissor gap' (P1); CA19-9's 'boundary signal failure' in early pancreatic cancer — sensitivity only 40%-50% (P13); HPV vaccination public awareness <20% — a P14 intervention gap.
A Unified Interpretation of 25+ Cancer Types
The Rongdu Principles framework has now been applied to decode and analyze every major cancer type in the CA Cancer Statistics series:
| Cancer Type | Core Rongdu Insight | Key Principle |
|---|---|---|
| Lung (Accelerating Mortality) | Immunotherapy's 'long-tail effect' drives P7 paradigm shift from palliation to functional cure | P5-P6-P7 |
| Breast (HER2-Low Revolution) | P4 HER2 expression window expanded by T-DXd's high DAR and bystander effect | P4-P6-P10 |
| Colorectal (Early-Onset Surge) | 'Reverse scissor gap' signals structural P7 transition; P11 left-colon biology mismatch | P1-P7-P10-P11 |
| Pancreatic (Survival Lock) | KRAS self-referential lock (P4) + P6 TME tolerance barrier → P7 zero-sum | P4-P6-P11-P13 |
| HCC (Viral→Metabolic Shift) | P4 viral vs metabolic information sources → P6 immune 'hot' vs 'cold' microenvironments | P4-P6-P11 |
| Gastric (Lauren Polarity) | Diffuse type's P6 'information shield' blocks CAR-T penetration; CLDN18.2 target-TME mismatch | P4-P6-P11 |
| Melanoma (Dual Drive) | BRAFi+MEKi induces 'hot→cold' P6 switching; targeted-immune sequencing depends on P6 coupling | P4-P6-P7-P10-P11 |
| Cervical (Elimination Paradox) | P4 HPV vaccine + P13 HPV DNA screening → P10 implementation gap | P4-P10-P13 |
| Prostate (Screening- Diagnosis Fracture) | P11 PSA-Risk mismatch: PSA's P4 information + P7 clinical decision gap | P4-P11 |
| Renal (VEGF-Immuno Synergy) | P4 VHL-HIF → P6 dual drive: angiogenesis + immunosuppression → P11 VEGF-TKI+PD-1 synergy | P4-P6-P7-P10-P11 |
What We Are NOT Saying
We are not claiming that the Rongdu Principles are a new theory of cancer biology that replaces existing knowledge.
We are claiming that the Rongdu Principles provide a unified language — a meta-language — for describing, explaining, and predicting cancer phenomena that currently appear disconnected.
We are not claiming that the Rongdu Principles can replace clinical judgment.
We are claiming that the Rongdu Principles can augment clinical judgment — by providing a systematic framework for asking the right questions at the right time.
We are not claiming that the Rongdu Principles are complete or final.
We are claiming that the Rongdu Principles are self-referential (P0) — they acknowledge their own boundaries and invite correction and evolution.
Invitation to the Global Oncology Community
To Researchers
- Test the Rongdu Principles framework against your experimental data
- Map your findings onto the P1-P16 coordinate system
- Identify the 'anomalous signals' (P1) and the 'hierarchical matching conditions' (P11) in your work
- Join us in refining the theoretical foundations
To Clinicians
- Apply the three laws to your daily clinical challenges
- Ask: What layer is affected? What is the anomalous signal? What is the boundary? What is the transition direction?
- Share your clinical observations — every 'treatment failure' is an 'anomalous signal' waiting to be decoded (P1)
- The framework is designed to be a tool, not a replacement for your clinical expertise
To Biotech Entrepreneurs
- Position your technology within the P1-P16 framework
- Identify the 'layer' where your innovation operates
- Design 'disruptive technologies' that address the mismatches uncovered by the framework
- Leverage our patent and IP services to protect your innovations at the right layer
To Policymakers
- Apply the framework to health disparities and cancer control strategies
- Recognize that differences are not single-layer problems — they are P1-P10 cross-layer lockings
- Design 'decoupling' interventions that address multiple layers simultaneously
- Join the global effort to make cancer a 'managed chronic information disease,' not a 'biological death sentence'
How to Engage
The Rongdu Principles framework is open for collaboration, critique, and application:
We offer:
- Top Journal Decoding — Analyzing the latest breakthroughs through the Rongdu Principles lens
- Disruptive Technology Design — P1-P16 architecture-based solutions for next-generation cancer control
- Hierarchical Transition Window Identification — Predicting when systems approach their 'capacity limits'
- Patent & IP Services — International patent agency | Domestic patent agency | Patent化 of research | Lunar Intellectual Property Registration: www.hrpp.org.cn
Contact: rongduyuanli@163.com
Further Reading: Full theory of the 16 Rongdu Principles at www.zzzk.org.cn
The Next Frontier: A Call to Co-Create
Cancer is not the 'enemy.' Cancer is the messenger. It is the information system telling us that the organism has lost its hierarchical coherence.
The Rongdu Principles framework offers a way to decode the message rather than simply attack the messenger.
We invite you — the global oncology community — to join us in this next phase of the journey:
- To test the framework against your data
- To refine the framework with your insights
- To apply the framework to your challenges
- To challenge the framework where it falls short
- To build the framework together
The 100-issue series is not the end. It is the beginning.
The future of oncology is not about 'more cells.' It is about 'better information.'
We look forward to working with you.
Zhuanzhi Think Tank
Chengdu Zhuanzhi Lihu Digital Technology Co., Ltd.
September 2026
Contact: rongduyuanli@163.com
Lunar Intellectual Property Registration: www.hrpp.org.cn
The Rongdu Principles are offered to the global community for use, critique, and development. The framework is self-referential (P0) — it acknowledges its own boundaries and invites correction and evolution. We welcome all contributions that move oncology closer to a unified information-based understanding of cancer.
